Indian government officials discuss supply chain routes, with maps and documents spread across a table.
India’s pharmaceutical industry is facing continued supply chain risks in securing essential petrochemicals due to the ongoing conflict in West Asia. While the government has implemented a customs duty waiver to alleviate some cost pressures, industry experts emphasize that the primary challenges revolve around supply chain disruptions and ensuring timely movement of materials.
The government’s intervention aims to stabilize the supply of vital inputs and reduce overall input costs for the pharmaceutical sector. However, geopolitical tensions add complexity to the supply chain, potentially impacting production timelines and cost efficiencies.
The customs duty waiver offers a degree of financial relief, yet the logistical hurdles in the region remain a significant concern for pharma companies. Ensuring a stable supply of petrochemicals is critical for maintaining consistent drug production and meeting domestic and export demands.
Industry stakeholders are closely monitoring the situation and working to diversify supply sources and optimize logistics to mitigate potential disruptions. The government’s role in facilitating smoother supply chains will be crucial in the coming months to minimize the impact on the pharmaceutical sector.
About the Author
